Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision oncology therapeutics targeting specific tumor vulnerabilities. The company's lead asset NXP800 is a SRC kinase inhibitor in Phase 1b/2 trials for platinum-resistant ovarian cancer and other solid tumors, while NXP900 targets CDK2 for ovarian and uterine cancers. With zero revenue and negative operating cash flow of approximately $30M annually, the company is entirely dependent on capital markets funding and clinical trial success to drive valuation.
Nuvectis operates a classic clinical-stage biotech model with no current revenue generation. The company burns cash developing proprietary oncology compounds through clinical trials, seeking FDA approval for commercialization. Value creation depends on demonstrating clinical efficacy and safety in trials, obtaining regulatory approval, and either commercializing independently or partnering with larger pharma companies for milestone payments and royalties. With a 2.38x current ratio and zero debt, the company has approximately 2-3 years of runway at current burn rates before requiring additional capital raises through equity offerings or partnerships. Pricing power post-approval would be substantial given orphan drug designations and limited competition in platinum-resistant ovarian cancer.
Clinical trial data readouts for NXP800 in platinum-resistant ovarian cancer - objective response rates and progression-free survival endpoints
FDA regulatory milestones including IND clearances, fast track designations, and breakthrough therapy designations
Partnership announcements with major pharmaceutical companies for co-development or commercialization rights
Capital raises and cash runway updates - dilution concerns versus funding adequacy
Competitive clinical data from rival SRC inhibitors or CDK2 inhibitors in similar indications
Conference presentations at ASCO, ESMO, or SGO showcasing mechanism-of-action and preliminary efficacy
Binary clinical trial risk - single Phase 2/3 failure could render pipeline worthless and trigger going-concern issues given pre-revenue status
FDA regulatory pathway uncertainty for novel mechanisms in orphan indications with limited precedent for approval standards
Reimbursement pressure from payers even post-approval given healthcare cost containment trends and scrutiny of high-priced oncology drugs
Patent cliff risk if composition-of-matter patents expire before achieving commercial scale, enabling generic competition
Larger pharmaceutical companies developing competing SRC inhibitors with superior resources for faster trial enrollment and broader indication pursuit
Alternative mechanisms targeting platinum-resistant ovarian cancer including PARP inhibitors, antibody-drug conjugates, and immunotherapy combinations gaining market share
Acquisition risk by competitors seeking to eliminate pipeline competition before commercialization
Dilution risk from future equity raises - with $30M annual burn and $200M market cap, significant shareholder dilution likely required before revenue generation
Going-concern risk if clinical setbacks occur before securing partnership or additional financing, particularly given 2-3 year runway estimate
Warrant overhang or structured financing terms from prior capital raises that could pressure stock price during future financing events
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as drug development timelines are multi-year and driven by scientific/regulatory milestones rather than economic demand. However, severe recessions can impact capital availability for financing rounds and reduce institutional investor risk appetite for speculative biotech equities.
Rising interest rates negatively impact Nuvectis through multiple channels: higher discount rates compress NPV of distant future cash flows (post-2028 commercialization), making long-duration biotech assets less attractive; elevated rates increase opportunity cost versus risk-free treasuries, reducing speculative capital allocation to pre-revenue biotechs; and higher rates tighten venture capital and biotech-focused fund availability for follow-on financings. The 10-year treasury yield directly affects valuation multiples for clinical-stage companies.
Minimal direct credit exposure given zero debt on balance sheet. However, credit market conditions indirectly affect ability to secure non-dilutive financing such as venture debt or equipment financing. Tighter credit spreads and risk-off sentiment in high-yield markets correlate with reduced biotech IPO/PIPE activity, constraining future capital raising options.
growth - Attracts speculative growth investors and biotech-focused hedge funds willing to accept binary risk/reward profiles. The 42.6% three-month return and 11.5% one-year return reflect momentum-driven trading around clinical catalysts rather than fundamental cash flow analysis. Institutional ownership likely concentrated among healthcare specialist funds rather than broad index investors. Not suitable for value or income investors given negative earnings, zero dividends, and speculative nature.
high - Clinical-stage biotechs exhibit extreme volatility with beta typically 1.5-2.5x market. Single-day moves of 30-50% common around data readouts. The $200M market cap and likely thin float amplify volatility. Recent 42.6% three-month surge suggests event-driven volatility around anticipated clinical milestones or partnership speculation.
